Shanna M. Hogeling

Groningen, GR 9713GZ, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Sustained PRC1.1 activity preserves gene repression independently of PRC2.2 and restrains leukemic cell differentiation.

Sustained PRC1.1 activity preserves gene repression independently of PRC2.2 and restrains leukemic cell differentiation.

Journal: Nucleic acids research
Published: July 09, 2025

Potent synergy of DHODH and SREBP inhibition in acute myeloid leukemia via disruption of cholesterol and lipid metabolism.

Potent synergy of DHODH and SREBP inhibition in acute myeloid leukemia via disruption of cholesterol and lipid metabolism.

Journal: Haematologica
Published: March 28, 2025

Potent synergy of DHODH and SREBP inhibition in acute myeloid leukemia via disruption of cholesterol and lipid metabolism.

Potent synergy of DHODH and SREBP inhibition in acute myeloid leukemia via disruption of cholesterol and lipid metabolism.

Journal: Haematologica
Published: March 28, 2025

ΔNp73 isoform defines a TP53-mutant-like poor-risk subgroup of acute myeloid leukemia.

ΔNp73 isoform defines a TP53-mutant-like poor-risk subgroup of acute myeloid leukemia.

Journal: Cell reports. Medicine
Published: March 04, 2025

Metformin induces ferroptosis associated with lipidomic remodeling in AML.

Metformin induces ferroptosis associated with lipidomic remodeling in AML.

Journal: Blood advances
Published: February 07, 2025

Bleximenib, the novel menin-KMT2A inhibitor JNJ-75276617, impairs long-term proliferation and immune evasion in acute myeloid leukemia.

Bleximenib, the novel menin-KMT2A inhibitor JNJ-75276617, impairs long-term proliferation and immune evasion in acute myeloid leukemia.

Journal: Haematologica
Published: April 16, 2024

Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias.

Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias.

Journal: Blood
Published: September 12, 2023

M2 macrophages drive leukemic transformation by imposing resistance to phagocytosis and improving mitochondrial metabolism.

M2 macrophages drive leukemic transformation by imposing resistance to phagocytosis and improving mitochondrial metabolism.

Journal: Science advances
Published: April 14, 2023

Dietary methionine starvation impairs acute myeloid leukemia progression.

Dietary methionine starvation impairs acute myeloid leukemia progression.

Journal: Blood
Published: June 27, 2022

CombiFlow: Flow cytometry-based identification and characterization of genetically and functionally distinct AML subclones.

CombiFlow: Flow cytometry-based identification and characterization of genetically and functionally distinct AML subclones.

Journal: STAR protocols
Published: October 08, 2021

CombiFlow: combinatorial AML-specific plasma membrane expression profiles allow longitudinal tracking of clones.

CombiFlow: combinatorial AML-specific plasma membrane expression profiles allow longitudinal tracking of clones.

Journal: Blood advances
Published: April 19, 2021

The USP7-TRIM27 axis mediates non-canonical PRC1.1 function and is a druggable target in leukemia.

The USP7-TRIM27 axis mediates non-canonical PRC1.1 function and is a druggable target in leukemia.

Journal: iScience
Published: November 25, 2020
Showing 1-12 of 15

Last Updated: 09/26/2026